Prostar trial results so far

[Peterd110]

Here are the results of my prostar trial with Xtandi and EZH2 inhibitor.

Baseline labs : psa 7.72 and alkaline phos 368

Bone scan showed progression and ct scan was clear of lymph node Mets

Started medicine on 3/13.

Labs on 4/3: psa dropped to 3.44 and alkaline phos dropped to 121

4/29: bone scan showed improvement and no change in CT scan ( still no lymph node involvement)

Alkaline phos dropped further to 63 but psa jumped up to 4.63.

Pain in my tail bone has all but went away completely. I was surprised and disappointed that my psa increased given that my pain, alk phos and Mets on bone scan decreased significantly.

[Tall_Allen]

PSA is just one biomarker. It goes up when prostate cancer cells die. The more important results are the changes in clinical progression. I'd be very happy with those results.

[Peterd110 in reply to Tall_Allen]

Thank you for your input! I will try to be positive.

[timotur]

Peter, congrats and thanks for posting your excellent results... good to bring awareness of this trial to the board... seems very promising...

EZH2 inhibitor CPI-1205

An orally available selective inhibitor of the histone lysine methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, CPI-1205 selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, a histone lysine methyltransferase (HMT) class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis. Check for active clinical trials using this agent.